Global Diabetes Therapeutics Market Size study, by Product (Injectables, Oral antidiabetic Drugs) and Regional Forecasts 2022-2028

Global Diabetes Therapeutics Market Size study, by Product (Injectables, Oral antidiabetic Drugs) and Regional Forecasts 2022-2028

Global Diabetes Therapeutics Market is valued approximately USD 1389.83 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 10.40 % over the forecast period 2022-2028. Diabetes Therapeutics refers to various treatment techniques utilized for the treatment of a diabetic patient such as insulin injections, pumps, and oral drugs among others. Diabetes is a chronic metabolic disease that occurs when the pancreas is no longer able to produce insulin or the body is unable to fully utilize the insulin it produces. it is characterized by an elevated level of glucose that causes ill impacts on the heart. Increase in prevalence of diabetes due to increasing obesity among people caused by unhealthy diets and sedentary lifestyles. The increasing number of programs initiated by various healthcare organizations for raising awareness about diabetes. For Instance: according to the International Diabetes Federation (IDF), it was reported that approximately 537 million adults (20-79 years) are living with diabetes, and the number of people suffering from diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. In addition, the Centers for Disease Control and Prevention (CDC) in the U.S. announced the launch of the National Diabetes Prevention Program (National DPP), along with the partnership of public and private organizations. The National Diabetes Prevention Program aims to prevent or delay type 2 diabetes. Also, the increase in research and development in the healthcare sector, the introduction of advanced drug in the market and new product approvals in the market contribute to the growth of the diabetes market. Rise in the geriatric and obese population. according to the Center for Aging Better, in 2021, there are almost 12 million people aged 65 and over in the UK, with 3.2 million aged 80 and over thus increase in several geriatric populations is likely to increase the market growth during the forecast period. However, Various side effects associated with the long-term use of anti-diabetes drug impedes the growth of the market over the forecast period of 2022-2028.

The key regions considered for the Global Diabetes Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America and the Rest of the World. North America dominated the global insulin therapeutics market in 2021, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and the launch of new drugs in the region. The United States is expected to grow tremendously during the forecast period, owing to factors, such as the high prevalence of obesity and increasing awareness regarding diabetes care in the region.

Major market players included in this report are:
Astrazeneca plc
Boehringer Ingelheim Gmbh
Eli Lilly And Company
GlaxoSmithKline plc
Novartis AG
Novo Nordisk
Sanofi S.A
Takeda Pharmaceutical Company Limited
Johnson And Johnson MD&D
Merck And Co.

The objective of the study is to define the market sizes of different segments & countries in recent years and to forecast the values for the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:
By Product:
Injectables
Oral antidiabetic Drugs
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Diabetes Therapeutics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Astrazeneca plc
Boehringer Ingelheim Gmbh
Eli Lilly And Company
GlaxoSmithKline plc
Novartis AG
Novo Nordisk
Sanofi S.A
Takeda Pharmaceutical Company Limited
Johnson And Johnson MD&D
Merck And Co.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.